GSK, Merck enter into €3.7bn deal for novel cancer treatment
The M7824 is an investigational bifunctional fusion protein immunotherapy, which is currently under clinical development, including potential registration studies, for multiple difficult-to-treat cancers. Bintrafusp alfa is said to